10.1016/j.kisu.2021.11.003 2
[DOI] [PubMed] [Google Scholar] 194.Yahfoufi N., Alsadi N., Jambi M., Matar C
Figures 1B , 3 ) is not fully ameliorated by conventional subcutaneous insulin administration, most likely because subcutaneous administration of insulin cannot fully compensate for the normal portal delivery of insulin to the liver
BPC 157, also known as PLD-116, PL-10, PL14736 [9], or Bepectin [10,11,12,13,14,15,16,17], has recently attracted considerable attention as a potential drug candidate that is stable in acidic environments and has no serious adverse effects [18], although it has been known to cause pain and/or necrosis when injected in an aqueous solution or in physiological saline [19]